Previous Article | Next Article ![]()
Journal of Virology, June 2006, p. 5733-5739, Vol. 80, No. 12
0022-538X/06/$08.00+0 doi:10.1128/JVI.00125-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Department of Microbiology and Immunology, Cornell University, Ithaca, New York 14850
Received 18 January 2006/ Accepted 5 April 2006
|
|
|---|
|
|
|---|
Terminases consist of at least two subunits in all viral systems studied to date (7). Although obtaining direct evidence for the identity of the terminase subunits in herpesviruses has been hampered by the lack of an in vitro packaging system, several lines of indirect evidence have implicated the products of UL15 and UL28 (pUL15 and pUL28, respectively) as terminase components as follows: (i) pUL15 and pUL28 interact in vitro and in vivo with one another and in vitro with the portal protein pUL6 (1, 6, 11, 12, 22), (ii) pUL28 has been shown to bind DNA sequences necessary for formation of genomic ends (2), (iii) pUL15 contains a highly conserved Walker box motif that is essential for HSV DNA packaging and resembles motifs maintained in the ATPase domains of some bacteriophage terminases (9, 15, 23), and (iv) it is likely that the terminase functions are conserved, inasmuch as the homologs of pUL15 and pUL28 in human cytomegalovirus (hCMV), encoded by UL89 and UL56, respectively, which also interact, have been shown to form a complex with the hCMV portal protein and are required for DNA packaging (10, 13).
The approximately 19,000-Mr protein encoded by herpes simplex virus 1 (HSV-1) UL33 has also been shown to interact with pUL15 and pUL28 by immunoprecipitation from lysates of HSV-infected cells (6). Although its exact function is not known, pUL33, like pUL15 and pUL28, is required for DNA cleavage and packaging (3, 8). Thus, engineered mutations in any of these genes can cause empty capsids lacking DNA to accumulate in infected cells (3, 4, 20). Small amounts of pUL33, pUL15, and pUL28 have also been shown to associate with HSV-1 capsids, suggesting that they maintain their interaction during packaging (5, 18, 24).
Because it would provide information about the HSV terminase, one goal of the present work was to characterize the roles of the individual proteins in the formation of the pUL15/pUL33/pUL28 complex.
|
|
|---|
Antibodies. Polyclonal rabbit antisera recognizing the first 35 amino acids of pUL15 (designated UL15N), the C terminus of pUL15, and the entire UL28- and UL33-encoded proteins have been described previously (6, 17, 19). Actin antibody was purchased from Santa Cruz Biotechnology.
Plasmids. Plasmid pJB125 contained the UL15 cDNA in vector pCDNA3 (Invitrogen), whereas plasmid pJB112 contained the UL28 coding sequence cloned into this vector. To construct a shuttle plasmid (designated pJB401) to transfer UL28 sequences into a defined site within CV1 cells, pJB112 was cleaved with BamHI and EcoRV, and a 2.36-kb DNA fragment containing the entire UL28 open reading frame was isolated and cloned into pCDNA5/FRT vector (Invitrogen) at the BamHI and EcoRV sites. This vector contains the hygromycin resistance gene with an Flp recombinase targeting site (FRT site) embedded in the 5' coding sequence. To construct pJB433, a PCR amplicon from HSV-1(F) DNA containing the entire UL33 coding sequence was cloned into pCDNA3 at the HindIII and EcoRI sites. pJB433 was digested with HindIII and EcoRI, and the UL33 coding sequences were gel purified and cloned into pCDNA5/FRT at HindIII and EcoRI sites. The resultant plasmid was designated pJB481. The genotype of each plasmid was confirmed by DNA sequencing.
Transfections for transient expression. Ninety-five-percent-confluent cells were transfected with the plasmids indicated in Results by use of Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen). Cells were harvested at 24 h posttransfection and subjected to either immunoprecipitation or immunoblot analysis as described below.
Construction and maintenance of novel UL33- and UL28-expressing cell lines. Complementing cell lines were constructed by using the Flp-In-CV-1 system (Invitrogen) according to the manufacturer's protocol. Briefly, either pJB481 or pJB401 (see above) was cotransfected with a plasmid (pOG44) containing Flp recombinase under the control of a constitutive hCMV promoter/enhancer into an engineered cell line (Flp-CV1). This cell line was derived from CV1 cells (a derivative of Vero cells) and contains an Flp target sequence (FRT) at a single locus that also bears a lacZ gene fused to a gene encoding zeocin resistance. Transcription of the fused gene was driven by the simian virus 40 early promoter. The Flp recombination event was expected to cause insertion of the pCDNA5/FRT construct into the cellular genome at the integrated FRT site. Insertion of the pCDNA5/FRT construct at this site was expected to bring the simian virus 40 promoter and the ATG initiation codon in frame with the hygromycin resistance gene, with concomitant inactivation of the lacZ-Zeor fusion gene.
After recombination, cells resistant to hygromycin were selected by growth in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 200 µg/ml hygromycin B. Once hygromycin-resistant foci were identified, the cells were trypsinized and pooled. Monolayers of the entire population of cells containing either UL33 or UL28 were screened for the ability to complement the growth of the UL33 or UL28 null mutants, respectively. All tested cell populations were able to complement the replication of the corresponding viral null mutants (not shown), and the cells were designated CV33 and CV28, respectively. CV28 and CV33 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 200 µg/ml hygromycin B.
Immunoprecipitation and immunoblotting. Cells were washed with cold phosphate-buffered saline (PBS) and resuspended in radioimmunoprecipitation assay buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, 2 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 5 µg/ml leupeptin, 10 µg/ml pepstatin, 10 mM NaF, 0.1 mM Na3VO4). After incubation on ice for 30 min without sonication, the lysates (800 µl from 8.8 x 106 cells) were clarified at 14,000 rpm for 15 min at 4°C in a microcentrifuge. The supernatants of all lysates were precleared by reaction with preimmune rabbit serum and 30 µl of a 50% slurry of Gammabind G-Sepharose beads (Amersham Pharmacia Biotech) for 2 h at 4°C with constant rotation. After the beads were pelleted by centrifugation, the supernatants were incubated with rabbit antibodies directed against pUL15, pUL28, or pUL33 for 2 h at 4°C. Thirty microliters of a 50% slurry of Gammabind G-Sepharose beads was then added. The mixture was incubated overnight at 4°C with constant rotation. The beads were washed four times with excess radioimmunoprecipitation assay buffer, and immune complexes were eluted in loading buffer (62.5 mM Tris, pH 6.8, 2% sodium dodecyl sulfate [SDS], 5% ß-mercaptoethanol, 12.5% glycerol) and boiled for 10 min. The immunoprecipitated material was electrophoretically separated on 12% SDS-polyacrylamide gels, and proteins were transferred electrically to nitrocellulose. In some experiments, a portion of the lysates was denatured in loading buffer, electrophoretically separated, and transferred to nitrocellulose.
Nitrocellulose sheets were washed twice in PBS and blocked overnight in PBS supplemented with 10% nonfat dry milk (Carnation). Primary rabbit polyclonal antibodies directed against the C terminus of pUL15 or pUL28 were diluted 1:1,000 in PBS supplemented with 2% bovine serum albumin, whereas anti-pUL33 rabbit polyclonal antibody was diluted 1:400, as previously described (17). Actin-specific antibody was diluted 1:200 according to the manufacturer's protocol. The diluted antibodies were reacted with the blocked nitrocellulose sheets for 2 h at room temperature and washed, and horseradish peroxidase-conjugated anti-rabbit immunoglobulin G diluted 1:5,000 in PBS plus 2% bovine serum albumin was added for 2 h at room temperature. The bound immunoglobulins were revealed by enhanced chemiluminescence (Amersham Pharmacia Biotech). Where applicable, the image intensities of bands on immunoblots were quantified with a Molecular Dynamics PhosphorImager before exposure to radiographic film.
To strip and reprobe the immunoblots, developed blots were incubated in a buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% SDS, and 100 mM ß-mercaptoethanol at 50°C for 30 min as described in the ECL manual (Amersham), followed by immunoblotting as described above.
|
|
|---|
![]() View larger version (62K): [in a new window] |
FIG. 1. Immunoblot probed with anti-pUL33 polyclonal antibody. Vero cells were mock infected (Mock, lane 1) or infected with UL15 null ( 15, lanes 3 and 4), UL28 null ( 28, lanes 5 and 6), UL33 null ( 33, lane 2) or wild-type HSV-1(F) (F, lane 7) virus at a multiplicity of infection of 5 PFU/cell. At 18 h p.i., lysates of the cells were subjected to immunoprecipitations with anti-pUL15N ( 15N, lanes 5 and 7), anti-pUL28 ( 28, lanes 2 and 3), or anti-pUL33 ( 33, lanes 1, 4, and 6) polyclonal antibody. The immunoprecipitates were electrophoretically separated on a 12% SDS-polyacrylamide gel, transferred onto a nitrocellulose membrane, and probed with anti-pUL33 polyclonal antibody. Bound immunoglobulin was revealed by enhanced chemiluminescence. Virus and Ab, respectively, indicate the infecting virus and the antibody used for immunoprecipitation for that particular experiment.
|
The presence of pUL33 enhances the pUL15/pUL28 interaction. Cells were mock infected or were infected with wild-type HSV-1(F) or viral deletion mutants lacking UL15, UL28, or UL33. Lysates were prepared, clarified, and reacted with antibodies against pUL15N, pUL28, or pUL33, and the presence of pUL15 in the immunoprecipitations was monitored by immunoblotting. The anti-C-terminal pUL15 antiserum was used for immunoblotting throughout this study due to its high sensitivity and specificity in this assay. The UL15 protein was readily immunoprecipitated with the pUL15N-specific antibody from lysates of cells infected with wild-type virus (not shown) and the UL28 and UL33 deletion viruses (Fig. 2, lanes 4 and 5) but was not immunoprecipitated from lysates of mock- or UL15 deletion mutant-infected cells (Fig. 2, lanes 1 and 2). Reaction of HSV-1(F)-infected-cell lysates with pUL33-specific antibody caused coimmunoprecipitation of pUL15 (Fig. 2, lane 7), whereas pUL15/pUL33 coimmunoprecipitation did not occur in lysates of cells infected with the UL28 deletion virus (Fig. 2, lane 3). These observations were consistent with previous data (Fig. 1) demonstrating that pUL28 was necessary for the pUL15/pUL33 interaction. Importantly, antibody against pUL28 reacted with lysates of cells infected with the UL33 deletion virus immunoprecipitated only a portion of the pUL15 that was immunoprecipitated with its cognate antibody (compare Fig. 2, lanes 5 and 6). These data indicate that while pUL33 is ultimately dispensable for the pUL15/pUL28 interaction, it also acts in some way to enhance the interaction in infected-cell lysates.
![]() View larger version (33K): [in a new window] |
FIG. 2. Immunoblot probed with anti-pUL15 antibody. Vero cells were mock infected (Mock, lane 1) or infected with UL15 null ( 15, lane 2), UL28 null ( 28, lanes 3 and 4), UL33 null ( 33, lanes 5 and 6), or HSV-1(F) (F, lane 7) virus at a multiplicity of infection of 5 PFU/cell. At 18 h p.i., the cells were lysed and subjected to immunoprecipitation with antibodies against the N terminus of pUL15 ( 15N, lanes 1, 4, and 5), pUL28 ( 28, lane 6), or pUL33 ( 33, lanes 2, 3, and 7). The immunoprecipitates were probed for the presence of pUL15 by immunoblotting with an antibody directed against the C terminus of pUL15. Bound immunoglobulin was revealed by enhanced chemiluminescence. Virus and Ab indicate the infecting virus and the immunoprecipitating antibody, respectively.
|
![]() View larger version (45K): [in a new window] |
FIG. 3. Immunoblot probed with anti-pUL28 antibody. Vero cells were mock infected (Mock, lane 1) or infected with UL15 null ( 15, lanes 3 and 4), UL28 null ( 28, lane 2), UL33 null ( 33, lanes 5 and 6), or HSV-1(F) (F, lane 7) virus. At 18 h p.i., immunoprecipitations were performed with antibodies against the N terminus of pUL15 ( 15N, lanes 5 and 7), pUL28 ( 28, lanes 1, 3, and 6), or pUL33 ( 33, lanes 2 and 4). The immunoprecipitates were denatured, separated on denaturing polyacrylamide gels, and transferred onto a nitrocellulose membrane, followed by immunoblotting with pUL28-specific polyclonal antibody. Virus and Ab indicate the infecting virus and the immunoprecipitating antibody, respectively.
|
![]() View larger version (51K): [in a new window] |
FIG. 4. Immunoblots of CV33 cells (CV1 cells expressing pUL 33) transiently expressing pUL28 and/or pUL15. CV33 cells were mock transfected (Mock) or transfected with plasmids expressing the genes indicated above each lane (28, pUL28; 15, pUL15; 15+28, pUL15 and pUL28). Lysates were prepared 24 h later, and lysates (lanes 1 to 4) or immunoprecipitations from these lysates obtained using pUL33-specific antibody (lanes 5 to 8) were electrophoretically separated, transferred to nitrocellulose, and probed with the pUL28-specific antisera (A) or antisera against the C terminus of pUL15 (B).
|
![]() View larger version (71K): [in a new window] |
FIG. 5. Immunoblots of CV33 cell lysates immunoprecipitated with pUL15N- and pUL28-specific antibodies. CV33 cells were mock transfected (M, lane 1) or transfected with plasmids expressing UL28 (28, lane 2), UL15 (15, lane 3), or UL15 and UL28 (15+28, lane 4). Twenty-four hours later, lysates were prepared and immunoprecipitations (IP) were performed with antibodies directed against pUL28 ( 28, lanes 1 and 2) or the N terminus of pUL15 ( 15, lanes 3 and 4). Immunoblots of the immunoprecipitated material were probed with antibody directed against pUL33 (A). The same blots were stripped as described in Materials and Methods and reprobed with antibody against the C terminus of pUL15 (B).
|
![]() View larger version (21K): [in a new window] |
FIG. 6. Immunoblots of CV33 cells treated with proteosome inhibitors. CV33 cells (CV1 cells engineered to express pUL33) were treated for 6 h with the indicated compounds, at which time cell lysates were prepared and separated by SDS-polyacrylamide gel electrophoresis. After transfer to a nitrocellulose membrane, immunoblotting was performed using antibodies against pUL33 (upper panels) or actin as a loading control (lower panels).
|
As shown in Fig. 7, the presence of pUL28 correlated with a greatly increased level of pUL33-specific immunoreactivity in the CV33 cells, whereas expression of pUL15 did not increase the amount of detectable pUL33 above that obtained upon mock transfection (compare Fig. 7A, lanes 1 to 3). Coexpression of pUL15 and pUL28 also increased levels of pUL33 immunoreactivity (Fig. 7A, lane 4). These data indicate that UL28 causes increased amounts of pUL33 to accumulate in the CV33 cell line, whereas UL15 did not induce such effects. Taken together with the knowledge that pUL33 is normally degraded by the proteosome in CV33 cells, these data suggest that the increased stability of pUL33 conferred by expression of pUL28 is a consequence of the interaction of these proteins.
![]() View larger version (31K): [in a new window] |
FIG. 7. Immunoblots of pUL33 in the presence and absence of UL28 and UL15. CV33 cells were mock transfected (Mock) or transfected with plasmids expressing the indicated open reading frames (28, UL28; 15, UL15; 15+28, UL15 and UL28). Twenty-four hours later, cell lysates were prepared and separated by SDS-polyacrylamide gel electrophoresis. After transfer to a nitrocellulose membrane, immunoblotting was performed using the polyclonal antibody against pUL33 (A), the C terminus of pUL15 (B), or pUL28 (C) or actin as a loading control (D). (E) Vero cells were infected with the indicated virus ( 15, UL15 null virus; 28, UL28 null virus) or mock infected (Mock) and were incubated in the presence or absence of 10 mm lactacystin or the DMSO carrier from 12 to 18 h p.i. Immunoblots of lysates harvested at 18 h p.i. were probed with the antibody against pUL33. A cellular protein recognized by the pUL33 antibody served as a loading control.
|
pUL33 augments coimmunoprecipitation of pUL15 and pUL28 in a pUL28-expressing cell line. To determine if pUL33 could enhance the pUL15/pUL28 interaction in the absence of other HSV proteins, a UL28-expressing cell line (CV28) was mock transfected or transfected with expression plasmids containing UL33, UL15, or both. Twenty-four hours after transfection, cell lysates were prepared and reacted with antibody against pUL33, pUL15, or pUL28. The presence of pUL15 and pUL28 in the immunoprecipitated material was determined by immunoblotting.
The constitutively expressed UL28 protein was immunoprecipitated from lysates of mock-transfected CV28 cells by the pUL28-specific antibody (Fig. 8A, lane 2) and was coimmunoprecipitated with the pUL33-specific antibody from lysates of CV28 cells expressing pUL33 (Fig. 8A, lane 3). The UL28 protein of CV28 cells was not immunoprecipitated with the pUL33-specific antibody in the absence of pUL33 expression (Fig. 8A, lane 1). Surprisingly, expression of UL15 in CV28 cells followed by reaction with the pUL15N antibody immunoprecipitated pUL15 (Fig. 8B, lane 4) but not pUL28 (Fig. 8A, lane 4) from CV28 cells. These data suggest that in this cell line pUL33 augments the interaction of pUL15 and pUL28 in the absence of other viral proteins.
![]() View larger version (61K): [in a new window] |
FIG. 8. Immunoblots of proteins immunoprecipitated from a UL28-expressing cell line (CV28). CV28 cells were mock transfected (Mock, lanes 1 and 2) or transfected with plasmids expressing UL33 (33, lane 3), UL15 (15, lane 4), or UL15 and UL33 (15+33, lane 5). Twenty-four hours later, lysates of the cells were prepared and subjected to immunoprecipitation (IP) with antibodies directed against pUL33 ( 33, lanes 1 and 3), pUL28 ( 28, lane 2), or the N terminus of pUL15 ( 15N, lanes 4 and 5). An immunoblot of electrophorectically separated material was probed with antibody to pUL28 (A). The same immunoblot was stripped as described in Materials and Methods and reprobed with antibodies against the C terminus of pUL15 (B).
|
![]() View larger version (34K): [in a new window] |
FIG. 9. Immunoblots of lysates and immunoprecipitates of CV28 cells expressing putative terminase proteins probed with pUL15-specific antibody. (A) CV28 cells (CV1 cells expressing pUL28) were mock transfected (Mock, lanes 1 and 5) or were transfected with UL33 (33, lanes 2 and 6), UL15 (15, lanes 3 and 7), or UL15 and UL33 (15+33, lanes 4 and 8). Lysates were prepared 24 h posttransfection. Fifteen microliters of the lysates (lanes 1 to 4) or material immunoprecipitated with the pUL28-specific antibody (lanes 5 to 8) was electrophoretically separated, and immunoblots of the separated proteins were probed with antibody directed against the C terminus of pUL15. pUL15-specific immunoreactivity in the blot was quantified with a Molecular Dynamics PhosphorImager before exposure to radiographic film. (B, left histogram) The amount of pUL15 immunoreactivity in lane 7 was divided by the amount in lane 3. (B, right histogram) The amount of pUL15 immunoreactivity in lane 8 was divided by the amount in lane 4. These ratios differed by approximately 9.5-fold.
|
|
|
|---|
Because all of the interactions in both studies were identified in the context of a cell lysate, a further caveat is that other proteins may affect the interactions. Because few viral proteins other than pUL15 and pUL33 coimmunoprecipitate with pUL28 (6), it seems most likely that any augmentation of the interaction would be mediated by cellular proteins or perhaps transiently by viral proteins yet to be identified.
It was of interest to find that pUL33 augmented the interaction of pUL15 and pUL28 both in infected cells and when transiently expressed in uninfected mammalian cells. This represents the first identification of an activity of pUL33 that might be relevant to its role in the HSV DNA cleavage/packaging reaction. The relatively small pUL33 has no obvious DNA or ATP binding motifs that might be expected of a terminase subunit (14), and this is consistent conceptually with its primary role as an adapter to augment interaction between the DNA binding (likely pUL28) and ATPase (likely pUL15) subunits of the terminase. Because pUL33 interacts primarily with pUL28, it seems most likely that pUL33 enhances the pUL15/pUL28 interaction by optimizing pUL28's capacity to bind pUL15, perhaps by optimizing pUL28 folding. On the other hand, given the multifunctionality of most HSV proteins it also seems likely that pUL33 will exhibit other interesting activities upon more extensive analyses.
That the pUL15/pUL28/pUL33 complex can form independently of the capsid or portal under physiological conditions in infected cells is supported by the observation here (not shown) and elsewhere that pUL6 does not coimmunoprecipitate with pUL15, pUL28, or pUL33 from infected-cell lysates (6). Although antibodies can interfere with coimmunoprecipitations, it seems unlikely that three different antibodies to three different proteins would all fail to pull down the portal if the terminase/portal protein complex was soluble and intact. On the other hand, the lysates employed in these studies would not be expected to contain abundant amounts of nuclear proteins. If the terminase requires the portal vertex within an intranuclear procapsid for binding, as seems likely, the current studies would not be expected to detect a portal/terminase interaction because the lysates should not contain intact procapsids. That pUL6 and putative terminase components pUL15 and pUL28 can interact is supported by studies using transient-expression systems (22). Clearly, further studies of the distributions of the relevant protein complexes in HSV-infected cells are necessary to determine the sites of assembly and interaction of the putative terminase and portal encoded by pUL6.
This work was supported by Public Health Service grant GM50740 from the National Institutes of Health.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»